These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 17884270)

  • 21. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients.
    Chujo D; Yagi K; Asano A; Muramoto H; Sakai S; Ohnishi A; Shintaku-Kubota M; Mabuchi H; Yamagishi M; Kobayashi J
    Hypertens Res; 2007 Dec; 30(12):1205-10. PubMed ID: 18344626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An evidence-based hypothesis for beneficial effects of telmisartan on Marfan syndrome.
    Takagi H; Yamamoto H; Iwata K; Goto SN; Umemoto T;
    Int J Cardiol; 2012 Jun; 158(1):101-2. PubMed ID: 22459372
    [No Abstract]   [Full Text] [Related]  

  • 23. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
    Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
    Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease.
    Satoh M; Tabuchi T; Minami Y; Takahashi Y; Itoh T; Nakamura M
    Clin Ther; 2009 Oct; 31(10):2113-25. PubMed ID: 19922882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy.
    Sukumaran V; Watanabe K; Veeraveedu PT; Thandavarayan RA; Gurusamy N; Ma M; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
    Hypertens Res; 2010 Jul; 33(7):695-702. PubMed ID: 20535115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of telmisartan on insulin resistance and visceral fat distribution in Chinese hypertensive patients with obesity.
    Huang GZ; Tang YH; Wang BY; Zhang B; Hu TJ; Zhang L; Zhang XY; Zhong Y
    Saudi Med J; 2011 Oct; 32(10):1017-21. PubMed ID: 22008920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Positive added effect of telmisartan. New therapy alternative for a large collection of cardiovascular risk patients].
    MMW Fortschr Med; 2010 Feb; 152(8):48-9. PubMed ID: 20358766
    [No Abstract]   [Full Text] [Related]  

  • 28. Telmisartan in high-risk patients intolerant of ACE inhibitors.
    Link A; Reil JC; Selejan S
    Lancet; 2009 Feb; 373(9662):458; author reply 459. PubMed ID: 19200909
    [No Abstract]   [Full Text] [Related]  

  • 29. Telmisartan to prevent recurrent stroke: the PRoFESS study: was the baby thrown out with the bathwater?
    McInnes GT
    Stroke; 2009 May; 40(5):1938-40. PubMed ID: 19038906
    [No Abstract]   [Full Text] [Related]  

  • 30. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
    Cohn JN
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telmisartan in high-risk patients intolerant of ACE inhibitors.
    Hall A; Strauss MH
    Lancet; 2009 Feb; 373(9662):458; author reply 459. PubMed ID: 19200910
    [No Abstract]   [Full Text] [Related]  

  • 32. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
    Kishi T; Hirooka Y; Konno S; Sunagawa K
    J Hypertens; 2012 Aug; 30(8):1646-55. PubMed ID: 22728908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of RAS inhibition depends on baseline albuminuria.
    Ito S
    Nat Rev Nephrol; 2010 Jan; 6(1):10-1. PubMed ID: 20023682
    [No Abstract]   [Full Text] [Related]  

  • 34. Does the PPAR-γ-activating property of telmisartan provide a benefit in clinical practice?
    Fujimura A; Ushijima K; Ando H
    Hypertens Res; 2013 Feb; 36(2):183. PubMed ID: 23190691
    [No Abstract]   [Full Text] [Related]  

  • 35. [PPARgamma-activating properties of angiotensin receptor blockers].
    Ando H; Fujimura A
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():498-501. PubMed ID: 16895217
    [No Abstract]   [Full Text] [Related]  

  • 36. [Erectile dysfunction as a harbinger of cardiovascular events. Long-term vascular protection with telmisartan].
    Arnheim K
    MMW Fortschr Med; 2009 Aug; 151(34-35):62-3. PubMed ID: 19771798
    [No Abstract]   [Full Text] [Related]  

  • 37. Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.
    Baptista T; Martinez M; Lacruz A; Arellano A; Mendoza S; Beaulieu S; Hernández L; Contreras Q; Galeazzi T; Vargas D
    Schizophr Res; 2007 Jan; 89(1-3):350-2. PubMed ID: 17029751
    [No Abstract]   [Full Text] [Related]  

  • 38. Short-term dietary salt supplementation blunts telmisartan induced increases in plasma renin activity in hypertensive patients with type 2 diabetes mellitus.
    Chen AX; Jerums G; Baqar S; Lambert E; Somarajah G; Thomas G; O'Callaghan C; MacIsaac RJ; Ekinci EI
    Clin Sci (Lond); 2015 Sep; 129(5):415-22. PubMed ID: 25849646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telmisartan treatment of refractory proteinuria in a dog.
    Bugbee AC; Coleman AE; Wang A; Woolcock AD; Brown SA
    J Vet Intern Med; 2014; 28(6):1871-4. PubMed ID: 25270397
    [No Abstract]   [Full Text] [Related]  

  • 40. [What is better here: ACE inhibitor or AT1 blocker?].
    MMW Fortschr Med; 2008 Apr; 150(16):16-7. PubMed ID: 18557213
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.